|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001455,
umls-concept:C0013030,
umls-concept:C0016904,
umls-concept:C0030685,
umls-concept:C0033268,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0087111,
umls-concept:C0175413,
umls-concept:C0205191,
umls-concept:C0391871,
umls-concept:C0442805,
umls-concept:C0680255,
umls-concept:C1283071,
umls-concept:C1399358,
umls-concept:C1963578
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2008-9-11
|
|
pubmed:abstractText |
It has been proposed that striatonigral GABAergic transmission in the substantia nigra reticulata (SNr) is enhanced during Parkinson's disease and subsequent L-DOPA treatment. To evaluate this proposal we determined the effects of activating dopamine D1 receptors on depolarization induced [(3)H]-GABA release and on [(3)H]-cAMP accumulation in slices of SNr of rats with unilateral 6-OHDA lesions with and without l-DOPA treatment. Denervation increased depolarization induced D1-stimulated [(3)H]-GABA release, while repeated L-DOPA treatment further enhanced this response. Both also enhanced the effects of forskolin on [(3)H]-cAMP production and [(3)H]-GABA release, while neither modified the stimulating effects of 8-Br-cAMP on the release. These results shown that, after 6-OHDA lesions and l-DOPA treatment, cAMP signaling is enhanced. Furthermore, the results suggest that activation of sites in the signaling cascade downstream of cAMP synthesis is not required to increase release.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1-Methyl-3-isobutylxanthine,
http://linkedlifedata.com/resource/pubmed/chemical/Antiparkinson Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclic AMP,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Levodopa,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidopamine,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphodiesterase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D1,
http://linkedlifedata.com/resource/pubmed/chemical/Tritium,
http://linkedlifedata.com/resource/pubmed/chemical/gamma-Aminobutyric Acid
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0028-3908
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
704-11
|
|
pubmed:meshHeading |
pubmed-meshheading:18588904-1-Methyl-3-isobutylxanthine,
pubmed-meshheading:18588904-Analysis of Variance,
pubmed-meshheading:18588904-Animals,
pubmed-meshheading:18588904-Antiparkinson Agents,
pubmed-meshheading:18588904-Behavior, Animal,
pubmed-meshheading:18588904-Cyclic AMP,
pubmed-meshheading:18588904-Disease Models, Animal,
pubmed-meshheading:18588904-Dopamine Agents,
pubmed-meshheading:18588904-Functional Laterality,
pubmed-meshheading:18588904-Levodopa,
pubmed-meshheading:18588904-Male,
pubmed-meshheading:18588904-Oxidopamine,
pubmed-meshheading:18588904-Parkinsonian Disorders,
pubmed-meshheading:18588904-Phosphodiesterase Inhibitors,
pubmed-meshheading:18588904-Rats,
pubmed-meshheading:18588904-Rats, Wistar,
pubmed-meshheading:18588904-Receptors, Dopamine D1,
pubmed-meshheading:18588904-Substantia Nigra,
pubmed-meshheading:18588904-Time Factors,
pubmed-meshheading:18588904-Tritium,
pubmed-meshheading:18588904-gamma-Aminobutyric Acid
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
|
|
pubmed:affiliation |
Departamento de Fisiología, Biofísica y Neurociencias. Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional. Apartado Postal 14-740, 07000 México D.F. México.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
